Press Releases

• Licensing-relevant study to examine the efficacy of MGN1703 in the treatment of metastasized colorectal cancer

• The multicenter study will start immediately after approval

• Application submitted for approval of a clinical study I/II
  
  
• Second MOLOGEN product candidate moves into clinical phase

• Promising cancer drug set to enter second stage of development
• New patents in the US for innovative product candidates

• Cancer drug MGN1703 demonstrates excellent tolerability in phase 1b study
  
  
• Application for phase 2 study on drug approval to be submitted soon

• Excellent tolerability of the cancer drug MGN1703 demonstrated
  
  
• Provisional evaluation of effectiveness indicates tremendous potential

• Patent protection in the USA for innovative product candidate
• Preparations for application for clinical studies with cell-based gene therapy of renal cancer

A licensee of MOLOGEN AG has initiated arbitration proceedings at the German Arbitration Institute. The background to this is the request made by the current licensee to return the licence it acquired to market cell-based gene therapy for the...